Company Overview of Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. discovers and develops novel antifungal agents through a proprietary medicinal chemistry platform. Its product includes VT-1161, an oral agent that is in Phase IIa clinical trials for the treatment of moderate to severe acute vulvovaginal candidiasis; and moderate to severe interdigital tinea pedis, a dermatologic infection. The company is also developing VT-1129, an oral agent for the treatment of cryptococcal meningitis, an invasive fungal infection of the lining of the brain and spinal cord; and VT-1598 and related analogues, which are in preclinical development to identify the optimal candidate to advance in development as an oral and intravenous therapy for ...
4505 Emperor Boulevard
Durham, NC 27703
Key Executives for Viamet Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Chief Business & Financial Officer
Compensation as of Fiscal Year 2015.
Viamet Pharmaceuticals, Inc. Key Developments
Viamet Pharmaceuticals Appoints Oren Cohen as Chief Medical Officer
Oct 14 15
Viamet Pharmaceuticals, Inc. announced the appointment of Oren Cohen, M.D., as Chief Medical Officer to further strengthen the company’s management team. Dr. Cohen is an authority on the development of drugs for the treatment of infectious diseases and multiple other indications. Prior to joining Viamet, Dr. Cohen served as Senior Vice President and Global Head, Early Clinical Development as well as Chief Medical Officer for Quintiles Inc., where he was involved in the oversight of over 200 industry-sponsored clinical trials across numerous therapeutic areas.
Viamet Pharmaceuticals, Inc. Receives QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis
Sep 16 15
Viamet Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1129, the company’s novel candidate for the treatment of cryptococcal meningitis. Created under the Generating Antibiotics Incentives Now (GAIN) Act of 2012, QIDP designation provides Viamet with significant incentives for the development of VT-1129, including the potential for priority review by the FDA, eligibility for fast-track status, and a five-year extension of marketing exclusivity under the Hatch-Waxman Act. The company also announced that VT-1129 will be highlighted in two presentations at the 2015 American Society for Microbiology (ASM) Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Society of Chemotherapy (ISC) International Congress of Chemotherapy and Infection (ICC).
Viamet Pharmaceuticals, Inc. and the Mycoses Study Group Education & Research Consortium Establish Collaboration to Advance Novel Therapy for Cryptococcal Meningitis
Aug 26 15
Viamet Pharmaceuticals, Inc. and the Mycoses Study Group Education & Research Consortium announced the establishment of a strategic collaboration to advance a novel therapy for cryptococcal meningitis and other life-threatening fungal infections. This collaboration will combine the antifungal drug discovery and development expertise of Viamet with the strategic clinical development expertise of the MSGERC. Cryptococcal meningitis is a life-threatening invasive fungal infection of the brain and spinal cord that occurs most often in immunocompromised patients, including those with HIV infection, transplant recipients and oncology patients. In preclinical studies, VT-1129 has demonstrated the ability to completely eradicate the fungal pathogen that causes cryptococcal meningitis from the central nervous system.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|